Physician profile
Jerome I Barr
NPI 1396914867
$5,596.26
in general payments reported to CMS, 2019-2025
25 companies · $888 in 2025
The $888 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $518 · 2021: $635 · 2022: $856 · 2023: $979 · 2024: $1,067 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,514 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $350 · Education: $70.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,513.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $350.00 |
| Education | $70.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,334.94 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| Abbvie INC. | $1,023.17 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $555.80 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $372.59 | 2022-2025 | Tremfya |
| Glaxosmithkline, LLC. | $348.10 | 2019-2023 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $309.91 | 2021-2024 | Saphnelo |
| Janssen Biotech, INC. | $271.65 | 2019-2025 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $262.98 | 2020-2023 | Taltz |
| Aurinia Pharma U.S., INC. | $152.25 | 2024 | Lupkynis |
| Pfizer INC. | $133.12 | 2019-2023 | |
| Horizon Therapeutics Plc | $120.29 | 2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $104.64 | 2019-2021 | |
| Cardinal Health 110 LLC | $100.00 | 2021 | |
| Genzyme Corporation | $89.75 | 2019-2025 | |
| US Oncology Corporate, INC. | $84.65 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $66.66 | 2020-2023 | Acthar |
| Sanofi-Aventis U.S. LLC | $65.89 | 2019-2020 | |
| Ucb, INC. | $55.80 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $31.79 | 2022-2024 | Strensiq |
| Fidia Pharma USA INC. | $27.95 | 2019-2023 | Hymovis, Triluron |
| Ani Pharmaceuticals, INC. | $26.14 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $20.16 | 2023 | Opsumit |
| Sandoz INC. | $13.44 | 2024 | Hyrimoz |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Ferring Pharmaceuticals INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Barr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.